Arcutis to Unveil Key ZORYVE Data at AAD 2026, Expanding Pediatric Dermatology Footprint
Event summary
- Arcutis will present new clinical data for ZORYVE at the 2026 AAD Annual Meeting, including late-breaking podium results from the INTEGUMENT-INFANT Phase 2 trial in infants aged 3–<24 months with atopic dermatitis.
- Five-minute poster presentation on long-term caregiver-reported outcomes from the INTEGUMENT-OLE Phase 3 trial in children aged 2–5 years with mild to moderate atopic dermatitis.
- Additional data from STRATUM Phase 3 trial subgroup analysis for seborrheic dermatitis and PASI outcomes from DERMIS-1/2 and ARRECTOR trials in plaque psoriasis will be presented in e-posters.
The big picture
Arcutis is positioning itself as a leader in immuno-dermatology by expanding the clinical evidence base for ZORYVE across multiple inflammatory skin conditions. The focus on pediatric populations, particularly infants, highlights a strategic push into an underserved segment of the dermatology market. With ZORYVE already established as a top-prescribed branded therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis, Arcutis aims to solidify its competitive edge through continuous innovation and clinical validation.
What we're watching
- Pediatric Market Expansion
- Whether Arcutis can leverage the INTEGUMENT-INFANT trial results to secure regulatory approval for ZORYVE in infants, expanding its market reach.
- Clinical Efficacy Validation
- How the long-term caregiver-reported outcomes from the INTEGUMENT-OLE trial will impact physician and patient confidence in ZORYVE for pediatric atopic dermatitis.
- Competitive Positioning
- The pace at which Arcutis can differentiate ZORYVE in the competitive dermatology market, particularly against established treatments for seborrheic dermatitis and plaque psoriasis.